Cargando…

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)

Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection experience a recurrence, and the risk of recurrence incr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khanna, Sahil, Sims, Matthew, Louie, Thomas J., Fischer, Monika, LaPlante, Kerry, Allegretti, Jessica, Hasson, Brooke R., Fonte, Allyson T., McChalicher, Christopher, Ege, David S., Bryant, Jessica A., Straub, Timothy J., Ford, Christopher B., Henn, Matthew R., Wang, Elaine E. L., von Moltke, Lisa, Wilcox, Mark H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495252/ https://www.ncbi.nlm.nih.gov/pubmed/36140013 http://dx.doi.org/10.3390/antibiotics11091234

Ejemplares similares

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020)

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials
por: Sims, Matthew, et al.
Publicado: (2021)

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2022)

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
por: McGovern, Barbara H, et al.
Publicado: (2020)

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
por: Fareed, Shaaz, et al.
Publicado: (2018)

1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2021)

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
por: Sims, Matthew, et al.
Publicado: (2023)

Genome Wide Analysis Reveals Host Genetic Variants that Associate with Reduction in Clostridium difficile Infection Recurrence (rCDI) in Patients Treated with Bezlotoxumab
por: Shaw, Peter, et al.
Publicado: (2017)

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021)

RCDI/eRCDI: a web-server to estimate codon usage deoptimization
por: Puigbò, Pere, et al.
Publicado: (2010)

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023)

Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
por: Henn, Matthew, et al.
Publicado: (2017)

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
por: McChalicher, Christopher W J, et al.
Publicado: (2023)

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018
por: Viprey, Virginie F, et al.
Publicado: (2022)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
por: Bobilev, Dmitri, et al.
Publicado: (2019)

Clostridioides difficile infection (CDI) during the COVID-19 pandemic
por: Spigaglia, Patrizia
Publicado: (2022)

470. Concomitant Antibiotic Use and Death Among a National Cohort of Veterans With Clostridium difficile Infection (CDI)
por: Appaneal, Haley, et al.
Publicado: (2018)

Predictors of 30-day All-cause Mortality in Veterans with First Recurrence of Clostridium difficile Infection (CDI)
por: Morrill, Haley, et al.
Publicado: (2017)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

Determinates of Clostridioides difficile infection (CDI) testing practices among inpatients with diarrhea at selected acute-care hospitals in Rochester, New York, and Atlanta, Georgia, 2020–2021
por: Fridkin, Scott K., et al.
Publicado: (2023)

1211. Response to Fecal Microbiota Transplant (FMT) in Refractory Clostridioides difficile Infection (CDI) is Modest Compared to Recurrent CDI in Hospitalized Patients
por: Shin, Jae Hyun, et al.
Publicado: (2020)

COVID-19 and Clostridioides difficile infection (CDI): Possible implications for elderly patients
por: Spigaglia, Patrizia
Publicado: (2020)

Incidence of Clostridioides difficile infection (CDI) related to antibiotic prescribing by GP surgeries in Wales
por: Tydeman, Florence, et al.
Publicado: (2021)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI
por: Dicks, Leon M. T.
Publicado: (2023)

2’-Fucosyllactose inhibits proliferation of Clostridioides difficile ATCC 43599 in the CDi-screen, an in vitro model simulating Clostridioides difficile infection
por: Wiese, Maria, et al.
Publicado: (2022)

The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection
por: Mullish, Benjamin H., et al.
Publicado: (2021)

Reductions in inpatient fluoroquinolone use and postdischarge Clostridioides difficile infection (CDI) from a systemwide antimicrobial stewardship intervention
por: Jones, K. Ashley, et al.
Publicado: (2021)

Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)
por: Manthey, Carolin F., et al.
Publicado: (2019)

Extraintestinal Clostridioides difficile Infection (CDI): A Recurrent Battle with Resilient Abdominal Wall Abscess
por: Chinnappan, Justine, et al.
Publicado: (2023)

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
por: Garey, Kevin W., et al.
Publicado: (2023)

Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
por: Normington, Charmaine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_347mbd6hdmparuq129pgh7tc6v